MedTrace Logo

Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

NCT01768689 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-06-07

No results posted yet for this study

Summary

Adherence to tyrosine kinase inhibitors is associated with improved outcomes in chronic myeloid leukemia patients. Hence, improved adherence might improve CML patients' prognosis.

Decreased adherence is a common problem in such patients, with non-adherence in up to 30% of patients in several studies. Recently, an emphasis has been placed on improving patient's adherence to tyrosine kinase inhibitors in these patients. However, there is no prospective high-quality evidence showing that adherence can be improved in these patients.

Therefore, the investigators hypothesize that adherence-encouraging interventions improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia patients.

Conditions

  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Medication Adherence

Interventions

BEHAVIORAL

Adherence-encouraging interventions - Group meeting

One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement

BEHAVIORAL

Adherence-encouraging interventions - Individual meetings

Individual meetings focusing on adherence issues with a multidiscilinary team

BEHAVIORAL

Adherence-encouraging interventions - Monthly phone calls

Monthly phone calls to detect urgent adherence-related issues

Sponsors & Collaborators

  • pia raanani

    lead OTHER

Principal Investigators

  • Pia Raanani, MD · Rabin Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01768689 on ClinicalTrials.gov